1. Tap, W. D. et al. J. Clin. Oncol. 37 (Suppl.), abstr LBA3 (2019).
2. Lilly to Establish an Access Program for Patients as it Prepares to Withdraw Lartruvo from the Global Market. Eli Lilly and Company,
https://investor.lilly.com/news-releases/news-release-details/lilly-establish-access-program-patients-it-prepares-withdraw
(2019).
3. Ryll, B. Nat. Rev. Clin. Oncol.
https://doi.org/10.1038/s41571-019-0230-4
(2019).
4. Hernandez, R. The Accelerated Rise and Fall of Olaratumab in Sarcoma. Cancer Therapy Advisor,
https://www.cancertherapyadvisor.com/home/news/conference-coverage/american-society-of-clinical-oncology-asco/asco-2019/sarcoma-olaratumab-rise-and-fall-treatment/
(2019).
5. Gyawali, B. & Kesselheim, A. S. Nat. Rev. Clin. Oncol. 15, 596–597 (2018).